Breaking Finance News

Novavax, Inc. (NASDAQ:NVAX) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Novavax, Inc. (NASDAQ:NVAX) to Hold in a report released on 9/21/2016.

Previously on 09/20/2016, Chardan Capital released a statement about Novavax, Inc. (NASDAQ:NVAX) reduced the target price from $5.75 to $1.50. At the time, this indicated a possible upside of 0.01%.

Just yesterday Novavax, Inc. (NASDAQ:NVAX) traded 5.12% higher at $1.49. Novavax, Inc.’s 50-day moving average is $6.38 and its 200-day moving average is $6.11. The last stock price is down -63.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 70,923,620 shares of NVAX traded hands, up from an average trading volume of 14,086,300

Recent Performance Chart

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. has 52 week low of $1.16 and a 52 week high of $9.23 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its target price, a total of 8 analysts have released a report on NVAX. The one year price target is $15.39 with five firms rating the stock a strong buy, 3 brokers rating the stock a buy, zero brokerages rating the company a hold, zero analysts rating the company a underperform, and lastly 0 brokers rating the stock a sell.

Brief Synopsis On Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *